04262017Headline:

Kansas City, Missouri

HomeMissouriKansas City

Email Brett Emison Brett Emison on LinkedIn Brett Emison on Twitter Brett Emison on Facebook Brett Emison on Avvo
Brett Emison
Brett Emison
Attorney • (800) 397-4910

FDA Study Finds Increased Risk of Blood Clots For Yaz, Other Drospirenone Contraceptives

Comments Off

FDA links Yaz to Increased Risk of Blood ClotsFor more than two years, I have been documenting the fact that Yaz, Yasmin and Ocella lead to serious and life-threatening side effects. Yaz, Yasmin, Ocella, and Beyaz contain the artificial progestin drospirenone combined with estrogen, which has been linked to serious side effects including blood clots, heart attack, stroke, pulmonary embolism, deep vein thrombosis (DVT), and gallbladder disease.

In a recently released FDA funded study that compared several different types of oral contraceptives, those that contain drospirenone were shown to increase blood clot risks by 75%. Unlike some other drugs with dangerous side effects, there are safe and effective alternatives to birth control pills containing drospirenone. This begs the question: Why are drug companies pushing newer drugs with dangerous side effects when they are no more effective than the other drugs on the market?

The obvious answer is money – Yaz alone made Bayer Pharmaceuticals $1.6 Billion in 2010. In fact, Bayer marketed Yaz birth control so aggressively, Bayer received FDA warning letters about its deceptive advertising. The FDA found that Bayer overstated the efficacy of Yaz and minimized the risk of harmful side effects.

There are currently thousands of serious injury and wrongful death lawsuits related to these side effects being tried in the U.S. including a “multi-district litigation” (MDL) being handled in U.S. Federal Court.

The FDA needs to take action on this as well. At a minimum there should be a “black-box” warning on the packaging, informing users of the serious risks that they may face.

Read More:

[More on Yaz Side Effects]

(c) Copyright 2011 Brett A. Emison

Follow @BrettEmison on Twitter.